AIM Vaccine mRNA RSV Vaccine Submits for Clinical Trials in the U.S.
- Written by Reporters
Multiple Institutions Give AIM a "Buy" Rating
HONG KONG SAR - Media OutReach Newswire – 5 February 2025 - AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to the U.S. Food and Drug...Read more: AIM Vaccine mRNA RSV Vaccine Submits for Clinical Trials in the U.S.